E-LIB Suche - Ergebnisse für: Bril', S. V.

1

Study of stability and transition processes of formation of..:

Bobylev, V. M. ; Bril', S. V. ; Gusachenko, L. K..
Combustion, Explosion, and Shock Waves. 10 (1974) 3 - p. 309-316 , 1974

Link: https://doi.org/10.1007/..

2

Optimization of the granulation of glutamic acid:

Minina, S. A. ; Raisyan, V. D. ; Efimova, L. S....
Pharmaceutical Chemistry Journal. 14 (1980) 11 - p. 810-813 , 1980

Link: https://doi.org/10.1007/..

3

Development of technology for the manufacture of riboxin:

Zhitomirskii, Z. S. ; Naumchik, G. N. ; Pliskina, T. P....
Pharmaceutical Chemistry Journal. 13 (1979) 9 - p. 952-954 , 1979

Link: https://doi.org/10.1007/..

4

Development of an intestinally soluble coating based on an ..:

Minina, S. A. ; Efimova, L. S. ; Abramova, N. V...
Pharmaceutical Chemistry Journal. 12 (1978) 2 - p. 254-258 , 1978

Link: https://doi.org/10.1007/..

5

Quantitative analysis of hexamidine by use of UV-spectropho..:

Tiraspol'skaya, S. G. ; Kompantseva, E. V. ; Bril', A. S..
Pharmaceutical Chemistry Journal. 11 (1977) 2 - p. 273-275 , 1977

Link: https://doi.org/10.1007/..

6

P.057 Achievement of minimal symptom expression in acetylch..:

Bril, V ; Muppidi, S ; Howard Jr., JF...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51 (2024) s1 - p. S31-S31 , 2024

Link: https://doi.org/10.1017/..

7

P.043 Long-term safety, tolerability, and efficacy of efgar..:

Genge, A ; Pasnoor, M ; Bril, V...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S69-S69 , 2023

Link: https://doi.org/10.1017/..

8

P.044 Efficacy, safety, and tolerability of efgartigimod in..:

Bril, V ; Vu, T ; Karam, C...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S70-S70 , 2023

Link: https://doi.org/10.1017/..

9

P.045 Safety profile overview of Efgartigimod Clinical Tria..:

Bril, V ; Behin, A ; Gwathmey, K...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S70-S70 , 2023

Link: https://doi.org/10.1017/..

10

P.034 Minimal symptom expression following treatment with e..:

Siddiqi, Z ; Howard Jr, JF ; Bril, V...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S67-S67 , 2023

Link: https://doi.org/10.1017/..

11

P277 Long-term safety, tolerability, and efficacy of Efgart..:

Ashcraft, E. ; Bril, V. ; Pasnoor, M....
Neuromuscular Disorders. 33 (2023) - p. S179 , 2023

Link: https://doi.org/10.1016/..

12

20. Practical application of subcutaneous immunoglobulin fo..:

Schaik van, I.N. ; Bril, V. ; Geloven van, N....
Clinical Neurophysiology. 131 (2020) 3 - p. e9 , 2020

Link: https://doi.org/10.1016/..

13

O.33Subcutaneous immunoglobulin in myasthenia gravis: resul..:

Pasnoor, M. ; Bril, V. ; Levine, T....
Neuromuscular Disorders. 29 (2019) - p. S125 , 2019

Link: https://doi.org/10.1016/..

14

Subcutaneous immunoglobulin (SCIG) for maintenance treatmen..:

Cocito, D. ; Peci, E. ; Lauria Pinter, G....
Clinical Neurophysiology. 130 (2019) 1 - p. e10 , 2019

Link: https://doi.org/10.1016/..

15

Chronic stress, depression and personality type in patients..:

Bogdan, A. ; Barnett, C. ; Ali, A....
European Journal of Neurology. 27 (2019) 1 - p. 204-209 , 2019

Link: https://doi.org/10.1111/..